New Developments in Myeloma, An Issue of Hematology/Oncology Clinics of North America, 1st Edition
Author :
Peter Leif Bergsagel
Date of Publication: 03/2024
In this issue of Hematology/Oncology Clinics, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of New Developments in Myeloma. With the advent of next generation sequencing and immune profiling technologies, marked ad ...view more
In this issue of Hematology/Oncology Clinics, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of New Developments in Myeloma. With the advent of next generation sequencing and immune profiling technologies, marked advances have been made recently in the understanding of the molecular and immune pathogenesis of multiple myeloma. Yet even with these advances, there is a continual search for new therapeutic approaches. In this issue, top experts discuss a full range of clinically relevant topics in this complex and fast-changing field.
In this issue of Hematology/Oncology Clinics, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of New Developments in Myeloma. With the advent of next generation sequencing and immune profiling technologies, marked advances have been made recently in the understanding of the molecular and immune pathogenesis of multiple myeloma. Yet even with these advances, there is a continual search for new therapeutic approaches. In this issue, top experts discuss a full range of clinically relevant topics in this complex and fast-changing field.
Key Features
Contains 16 relevant, practice-oriented topics including molecular pathogenesis of multiple myeloma; monoclonal antibodies in the treatment of multiple myeloma; CAR-T cells in the treatment of multiple myeloma; management of newly diagnosed multiple myeloma today, and in the future; approach to high-risk multiple myeloma; new therapies on the horizon for relapsed refractory multiple myeloma; and more.
Provides in-depth clinical reviews on new developments in myeloma, offering actionable insights for clinical practice.
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Author Information
Edited by Peter Leif Bergsagel, M.D, Novel Therapeutics for Cancer Research, Director, Mayo Clinic SPORE in Multiple Myeloma, Co-Director, Hematologic Malignancies Program, Mayo Clinic Cancer Center, Consultant, Division of Hematology/Oncology, Professor of Medicine, Mayo Clinic College of Medicine
Bring it with you - The Bookshelf app allows you to access books on your laptop, tablet or mobile, so your ebooks go where ever you are - online or offline.
Take notes - Highlight, bookmark and take notes and highlights automatically stay in sync no matter where you make them.
Listen to eBooks - When you need to go screenless, the Text-to-speech tool will read your book aloud.
Powerful search - The searching capabilities allow you to search keywords through all your eBooks, the entire Bookshelf Library and well as on Wikipedia.
Ecological - Manage your environmental impact with paperless books.
How to read your VitalSource eBooks
Purchase your VitalSource eBook on the Elsevier Health site
https://www.uk.elsevierhealth.com/new-developments-in-myeloma-an-issue-of-hematologyoncology-clinics-of-north-america-9780443130779.html310320New Developments in Myeloma, An Issue of Hematology/Oncology Clinics of North Americahttps://www.uk.elsevierhealth.com/media/catalog/product/9/7/9780443130779_3.jpg64.4985.99GBPInStock/Medicine and Surgery/Haematology/Clinics Review Articles1003356128391745310000In this issue of <i>Hematology/Oncology Clinics</i>, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of <b>New Developments in Myeloma</b>. With the advent of next generation sequencing and immune profiling technologies, marked advances have been made recently in the understanding of the molecular and immune pathogenesis of multiple myeloma. Yet even with these advances, there is a continual search for new therapeutic approaches. In this issue, top experts discuss a full range of clinically relevant topics in this complex and fast-changing field. In this issue of <i>Hematology/Oncology Clinics</i>, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of <b>New Developments in Myeloma</b>. With the advent of next generation sequencing and immune profiling technologies, marked advances have been made recently in the understanding of the molecular and immune pathogenesis of multiple myeloma. Yet even with these advances, there is a continual search for new therapeutic approaches. In this issue, top experts discuss a full range of clinically relevant topics in this complex and fast-changing field.00add-to-cart97804431307792024ProfessionalEdited by Peter Leif Bergsagel, M.D20241Book152w x 229h (6.00" x 9.00")Elsevier2401 Mar 2024PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 10 DAYSEdited by <STRONG>Peter Leif Bergsagel</STRONG>, M.D, Novel Therapeutics for Cancer Research, Director, Mayo Clinic SPORE in Multiple Myeloma, Co-Director, Hematologic Malignancies Program, Mayo Clinic Cancer Center, Consultant, Division of Hematology/Oncology, Professor of Medicine, Mayo Clinic College of MedicineClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
